GLP-1 receptor agonist toxicity: Difference between revisions
(Created page with "==Background== ==Clinical Features== ==Differential Diagnosis== ==Evaluation== ===Workup=== ===Diagnosis=== ==Management== ==Disposition== ==See Also== ==External Links== ==References== <references/>") |
|||
| (10 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
==Background== | ==Background== | ||
*GLP-1 receptor agonists are injectable medication used for diabetes management and weight loss | |||
*Poison control centers have reported increasing inquiries related to possible overdoses | |||
{{GLP-1 Agonist Types}} | |||
==Clinical Features== | ==Clinical Features== | ||
Similar to side effects normally associated with these medications, but worse: | |||
*[[Nausea/vomiting]] | |||
*[[Constipation]] | |||
*[[Epigastric pain]] | |||
*[[Headache]] | |||
*[[Tachycardia]] | |||
*Diaphoresis | |||
*[[Confusion]] | |||
*[[Delirium]] | |||
==Differential Diagnosis== | ==Differential Diagnosis== | ||
{{Nausea and vomiting DDX}} | |||
==Evaluation== | ==Evaluation== | ||
===Workup=== | ===Workup=== | ||
*CBC | |||
*Chemistry | |||
*LFTs + lipase | |||
===Diagnosis=== | ===Diagnosis=== | ||
*Typically a clinical diagnosis (based on history) | |||
==Management== | ==Management== | ||
*Symptomatic management | |||
**Anti-nausa medications (e.g., [[zofran]]) | |||
*Consider stopping other glucose-lowering (i.e, diabetic) medications | |||
==Disposition== | ==Disposition== | ||
*If symptoms can be controlled, patients can normally be discharged | |||
**Consider discharge with [[zofran]] and hold of diabetic medications for ~1 week | |||
==See Also== | ==See Also== | ||
*[[GLP-1 agonists]] | |||
==External Links== | ==External Links== | ||
| Line 27: | Line 45: | ||
==References== | ==References== | ||
<references/> | <references/> | ||
[[Category:Toxicology]] | |||
Latest revision as of 20:58, 31 January 2024
Background
- GLP-1 receptor agonists are injectable medication used for diabetes management and weight loss
- Poison control centers have reported increasing inquiries related to possible overdoses
GLP-1 Agonist Types
| Short Acting | Dose |
|---|---|
| Exenatide (Byetta) | 5-10 mcg SC bid |
| Liraglutide (Victoza, Saxenda) | 0.6-1.8 mg SC daily |
| Long Acting | |
| Exenatide (Bydureon) | 2 mg SC qwk |
| Albiglutide (Tanzeum) | 30-50 mg SC qwk |
| Dulaglutide (Trulicity) | 0.75-1.5 mg qwk |
- Lixisenatide (Lyxumia, Adlyxin)
- Semaglutide (Ozempic, Rybelsus, Wegovy)
- Tirzepatide^ (Mounjaro, Zepbound)
^Dual GLP-1 and GIP agonist
Clinical Features
Similar to side effects normally associated with these medications, but worse:
Differential Diagnosis
Nausea and vomiting
Critical
Emergent
- Acute radiation syndrome
- Acute gastric dilation
- Adrenal insufficiency
- Appendicitis
- Bowel obstruction/ileus
- Carbon monoxide poisoning
- Cholecystitis
- CNS tumor
- Electrolyte abnormalities
- Elevated ICP
- Gastric outlet obstruction, gastric volvulus
- Hyperemesis gravidarum
- Medication related
- Pancreatitis
- Peritonitis
- Ruptured viscus
- Testicular torsion/ovarian torsion
Nonemergent
- Acute gastroenteritis
- Biliary colic
- Cannabinoid hyperemesis syndrome
- Chemotherapy
- Cyclic vomiting syndrome
- ETOH
- Gastritis
- Gastroenteritis
- Gastroparesis
- Hepatitis
- Labyrinthitis
- Migraine
- Medication related
- Motion sickness
- Narcotic withdrawal
- Thyroid
- Pregnancy
- Peptic ulcer disease
- Renal colic
- UTI
Evaluation
Workup
- CBC
- Chemistry
- LFTs + lipase
Diagnosis
- Typically a clinical diagnosis (based on history)
Management
- Symptomatic management
- Anti-nausa medications (e.g., zofran)
- Consider stopping other glucose-lowering (i.e, diabetic) medications
Disposition
- If symptoms can be controlled, patients can normally be discharged
- Consider discharge with zofran and hold of diabetic medications for ~1 week